WASHINGTON, April 18- U.S. Supreme Court Chief Justice John Roberts on Friday denied a request by Teva Pharmaceutical Industries Ltd to stay a lower-court ruling in a patent case that favored the developers of generic versions of Teva's top-selling multiple sclerosis drug.» Read More
Americans may not be getting access to generic drugs, even if they are available, CNBC's David Faber reports on tonight's edition of "Business Nation."
Hollis-Eden Pharmaceuticals said the U.S. government has canceled its request for proposal for a contract for its drug to treat acute radiation syndrome, sending its shares spiraling.
Shares of Insmed plunged after the tiny biotech company said it will restructure operations due to recently settled litigation with rival Tercica, which will keep Insmed's treatment for short stature in children off the U.S. market.
CV Therapeutics said its angina drug was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
Pfizer said the FDA approved Lipitor for new uses including treating nonfatal heart attacks, fatal and nonfatal strokes, certain types of types of heart surgery, hospitalization for heart failure, and chest pain in patients with heart disease.
The Fast Money Five give their picks for the hottest trades. Tonight, the burning rubber rally, the call ahead of Costco earnings and more...
CV Therapeutics said on Tuesday its angina drug Ranexa was not effective in a study of acute and long-term treatment of patients with a type of heart disease known as acute coronary syndrome.
A judge in the New Jersey Vioxx personal injury trial on Monday rejected a motion that would give one of the plaintiffs in the trial another opportunity to collect damages based on negligence from drug maker Merck.
Brian from Missouri asked wither the slide we’re seeing today in the energy markets is going to help stocks. Also, what’s with this sell-off in the Euro and do you think it will continue? Eric Bolling answered....
It's time to step back from the madness and understand a basic tenet of the markets: Just because something negative happens somewhere, it doesn't mean the sky is falling. In fact, it could be good news for you. Here's why...
While no one was looking shares of Amgen, the world's biggest biotech company (by sales, not market cap--Genentech is #1 there) have fallen from nearly $76 on January 22nd to the low-60s. What happened? In a nutshell, the company has been buffeted by safety, reimbursement and competitive concerns about its biggest drug franchise known as the acronym EPO.
GlaxoSmithKline's claim to have one of the best new drug pipelines in the industry has suffered a setback with the loss of a number of experimental medicines in mid-stage clinical testing.
Gen-Probe has won U.S. approval to sell its Procleix blood test to detect the West Nile virus, a Food and Drug Administration spokeswoman said Friday.
A New Jersey jury found on Friday that Merck failed to provide adequate warnings about health risks tied to its withdrawn arthritis drug Vioxx in one case, but decided that it gave adequate warning in another in two suits tried simultaneously.
Drugmaker Bayer said Friday that it will cut 6,100 jobs, more than half of them in Europe, as it integrates Schering AG into its health care unit.
The fact that Cramer wants you in this sector may confuse you. Yes, we know, this group is responsible for the subprime-lending problem we’re seeing today, but this could end up helping investors.
After the trauma of a 416-point drop in the market, Cramer likes to go fishing – bottom fishing, actually. He has 25 years of experience angling through the wrecks of portfolios that belonged to less experienced fisherman and women, and today he’s going to share his secrets with you.
Federal health advisers recommended Tuesday that the government approve the first bird flu vaccine as a stopgap measure, despite evidence it wouldn't protect most people.
The American Heart Association issued new guidelines for Pfizer's Celebrex, advising doctors the painkiller should only be used as a last resort on patients who have heart disease or a risk of developing it, CNBC's Mike Huckman reported.
Merck's stock rose before the opening bell Monday after U.S. regulators asked for more data on rival Novartis' diabetes drug, which gives Merck a leg up in the race to launch a new class of diabetes drugs.